US EditionPublished • loading... • Updated
Other Patent Extension Attempts Threaten the Treasury
Summary by El Economista
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
The protection granted to Amgen biopharmaceuticals that allowed her to revive her Denosumab patent is already an unmovable fact, a failure that is outraged by its direct impact on the public treasury by blocking the acquisition of cheaper generic versions, which goes against the human rights of Mexicans who have the least.This medicine, vital for osteoporosis and bone cancer, will mean to the Mexican State a cost of 1.5 billion pesos in governme…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
